New technologies for stationary solar energy hold great promise for greater efficiency
News Highlights: New technologies for stationary solar energy hold great promise for greater efficiency
LAS CRUCES – A team of engineering researchers at New Mexico State University is advancing in the development of technologies that make fresh water production more efficient and cost-effective through the use of solar-powered stills. Their work could provide a viable solution for regions of the world with water shortages.
It is estimated that by 2050, more than 52% of the world’s population would live in water-stressed areas, and many of these areas are arid or semi-arid and have an abundance of solar energy. Solar powered stills are well suited to these regions or other places where there are no sustainable and affordable clean water options. Simple solar stills are used in many small scale desalination and distillation plants and have limited use in modern agricultural, industrial and
Share this article
Share this article
SHANGHAI, Jan. 13, 2021 /PRNewswire/ Zhongchao Inc. (NASDAQ: ZCMD) ( Zhongchao or the Company ), a healthcare services company offering patient management, online healthcare information, professional training and educational services, today announced that it co-sponsored the National Annual Conference for Standardized Liver Cancer Diagnosis and Treatment (the Annual Conference ) with China Association of Health Promotion and Education and Chinese Society of Liver Cancer.
In 2020, Zhongchao worked with medical associations and experts to jointly carry out a multi-year online education project on the diagnosis and treatment of primary liver cancer. This project aims to promote and implement the Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2019 Edition) (the Guidelines ) published by the National Health Commission of the People s Republic of China. Based on the professional interpretation and through its online
José M. Vega, M.D. Joins Moderna as Chief Safety Officer
José M. Vega, M.D. Joins Moderna as Chief Safety Officer
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Jos M. Vega, M.D. joined Moderna as Chief Safety Officer effective Monday, January 11, 2021. Dr. Vega will report to Chief Medical Officer Tal Zaks, M.D., Ph.D. Jos brings a strategic level of leadership and deep experience in drug development and pharmacovigilance in global biopharmaceutical companies including Merck and Amgen, said Dr. Zaks. I am thrilled to welcome Jos to the Moderna team as we enter the next phase of growth of our company.